Published online Feb 16, 2024. doi: 10.12998/wjcc.v12.i5.880
Peer-review started: October 16, 2023
First decision: November 28, 2023
Revised: December 12, 2023
Accepted: January 16, 2024
Article in press: January 16, 2024
Published online: February 16, 2024
Processing time: 106 Days and 19.5 Hours
Clinical studies have reported that patients with gastroesophageal reflux disease (GERD) have a higher prevalence of hypertension.
To performed a bidirectional Mendelian randomization (MR) analysis to investi
Eligible single nucleotide polymorphisms (SNPs) were selected, and weighted median, inverse variance weighted (IVW) as well as MR egger (MR-Egger) re
IVW analysis exhibited an increased risk of hypertension (OR = 1.46, 95%CI: 1.33-1.59, P = 2.14E-16) in GERD patients. And the same result was obtained in replication practice (OR = 1.002, 95%CI: 1.0008-1.003, P = 0.000498). Meanwhile, the IVW analysis showed an increased risk of systolic blood pressure (β = 0.78, 95%CI: 0.11-1.44, P = 0.021) and hypertensive heart disease (OR = 1.68, 95%CI: 1.36-2.08, P = 0.0000016) in GERD patients. Moreover, we found an decreased risk of Barrett's esophagus (OR = 0.91, 95%CI: 0.83-0.99, P = 0.043) in essential hypertension patients.
We found that GERD would increase the risk of essential hypertension, which provided a novel prevent and therapeutic perspectives of essential hypertension.
Core Tip: This study used a method of bidirectional Mendelian randomization, and its results highlighted that gastroesophageal reflux disease (GERD) was positively associated with the risk of essential hypertension, suggesting a new prevent strategy and therapeutic perspectives of essential hypertension in patients with GERD.